Trial · NCT07151157
Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease
NCT07151157, Not applicable, Active not recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease. Trials, record NCT07151157. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07151157
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Therapeutic Value of Sirolimus in Refractory Adult-Onset Still's Disease
- NCT number
- NCT07151157
- Status
- Active not recruiting
- Phases
- Not applicable
- Enrollment
- 3 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Adult-Onset Still's Disease
- Interventions
- add-on sirolimus therapy
- First posted
- 2025-09-03
- Last updated
- 2026-08-18
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | AOSD Disease Activity Score | at weeks 12 | Pouchot Systemic Score Scoring items (1 point each): fever; arthritis/arthralgia; rash; sore throat; hepatosplenomegaly; pericarditis/pleuritis; lymphadenopathy; abnormal liver function; leukocytosis; hyperamylasemia/thrombocytopenia; elevated ESR or CRP; other systemic manifestations (e.g., myalgia, fatigue). Total score: 0-12 points, with higher scores indicating greater disease activity. |
| Secondary | AOSD Disease Activity Score | Baseline (day before sirolimus) and at weeks 4, and 8 | Pouchot Systemic Score Scoring items (1 point each): fever; arthritis/arthralgia; rash; sore throat; hepatosplenomegaly; pericarditis/pleuritis; lymphadenopathy; abnormal liver function; leukocytosis; hyperamylasemia/thrombocytopenia; elevated ESR or CRP; other systemic manifestations (e.g., myalgia, fatigue). Total score: 0-12 points, with higher scores indicating greater disease activity. |
| Secondary | Serum C-reactive Protein (CRP) Concentration | Baseline (day before sirolimus) and at weeks 4, 8, and 12 | CRP will be measured from peripheral blood samples as a marker of systemic inflammation. |
| Secondary | Erythrocyte Sedimentation Rate (ESR) | Baseline (day before sirolimus) and at weeks 4, 8, and 12 | ESR will be assessed from peripheral blood samples to evaluate inflammatory activity. |
| Secondary | Concentration of Serum Ferritin | Baseline (day before sirolimus) and at weeks 4, 8, and 12 | Ferritin will be measured from peripheral blood samples as an indicator of disease activity and inflammation. |
| Secondary | Level of Soluble Interleukin-2 Receptor (sIL-2R) | Baseline (day before sirolimus) and at weeks 4, 8, and 12 | sIL-2R will be measured from peripheral blood samples as a marker of immune activation. |
| Secondary | Concentration of Inflammatory Cytokines (e.g., IL-6, TNF-α) | Baseline (day before sirolimus) and at weeks 4, 8, and 12 | Multiple inflammatory cytokines will be measured from peripheral blood samples to evaluate systemic inflammatory status. |
| Secondary | Number of participants with Clinical symptoms such as rash and arthralgia | Baseline (day before sirolimus) and at weeks 4, 8, and 12 | Changes in clinical symptoms such as rash and joint pain will be observed and recorded through physical examination. |
| Secondary | Expression level of ZFP36L2 in neutrophils | Baseline (day before sirolimus) and at weeks 4, 8, and 12 | Collect 10 mL of peripheral blood from patients and isolate neutrophils within 2 hours to measure the expression level of ZFP36L2. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07151157
GET https://conductscience.org/api/trials/v1/NCT07151157/registered